-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, March 15th, March 11-12, NMPA official website shows that CSPC’s nintedanib ethanesulfonate soft capsules and entecavir tablets have been approved for production and deemed to have been reviewed.
Ceftriaxone sodium for injection passed Consistency evaluation.
Nintanib ethanesulfonate soft capsule is a targeted anti-fibrosis drug, and CSPC won the first domestic imitation.
At present, CSPC has already reviewed 43 products.
Ceftriaxone sodium for injection passed Consistency evaluation.
Nintanib ethanesulfonate soft capsule is a targeted anti-fibrosis drug, and CSPC won the first domestic imitation.
At present, CSPC has already reviewed 43 products.
Nintanib ethanesulfonate soft capsule is a multi-target tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim.
It is the world's first approved for the treatment of idiopathic pulmonary fibrosis (IPF) Of targeted drugs.
In 2019, Ofev's global sales were US$1.
670 billion.
It is the world's first approved for the treatment of idiopathic pulmonary fibrosis (IPF) Of targeted drugs.
In 2019, Ofev's global sales were US$1.
670 billion.
Nintedanib has been approved for multiple indications worldwide.
The approved indications in China include idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive Fibrotic interstitial lung disease (PF-ILD).
At present, only CSPC has submitted an imitation application for nintedanib ethanesulfonate soft capsules in the domestic market.
CSPC successfully won the first imitation, and the indication is IPF.
The product of Hausen Pharmaceuticals is undergoing BE trials and is expected to become the second domestic manufacturer.
The approved indications in China include idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive Fibrotic interstitial lung disease (PF-ILD).
At present, only CSPC has submitted an imitation application for nintedanib ethanesulfonate soft capsules in the domestic market.
CSPC successfully won the first imitation, and the indication is IPF.
The product of Hausen Pharmaceuticals is undergoing BE trials and is expected to become the second domestic manufacturer.
Entecavir is a guanine nucleoside analog, which has an inhibitory effect on hepatitis B virus reverse transcriptase, and has the advantages of good safety and tolerability.
It has been recommended as a first-line antiviral drug by many authoritative hepatitis B diagnosis and treatment guidelines around the world.
Entecavir has been included in the first batch of centralized procurement.
Affected by the sharp price cuts in centralized procurement, its market has shown a shrinking trend.
It has been recommended as a first-line antiviral drug by many authoritative hepatitis B diagnosis and treatment guidelines around the world.
Entecavir has been included in the first batch of centralized procurement.
Affected by the sharp price cuts in centralized procurement, its market has shown a shrinking trend.
Sales of terminal entecavir in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, the sales of terminal entecavir in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 7.
6 billion yuan, and its sales in 2020H1 exceeded 1.
4 billion yuan, year-on-year A decline of 62.
70%.
Currently, there are 11 companies that have reviewed Entecavir tablets .
com, in 2019, the sales of terminal entecavir in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 7.
6 billion yuan, and its sales in 2020H1 exceeded 1.
4 billion yuan, year-on-year A decline of 62.
70%.
Currently, there are 11 companies that have reviewed Entecavir tablets .
Ceftriaxone sodium is a long-acting, broad-spectrum third-generation semi-synthetic cephalosporin antibiotic.
It produces antibacterial effects by inhibiting the synthesis of cell walls, and has high antibacterial activity against most gram-negative and positive bacteria.
It produces antibacterial effects by inhibiting the synthesis of cell walls, and has high antibacterial activity against most gram-negative and positive bacteria.
According to data from Mi Nei.
com, the sales of terminal ceftriaxone in China's public medical institutions exceeded 3.
8 billion yuan in 2019.
At present, there are 5 over-rated companies for ceftriaxone sodium for injection, including Qilu Pharmaceutical, Kelun Pharmaceutical, Jincheng Jinsu Pharmaceutical, Runze Pharmaceutical and CSPC.
com, the sales of terminal ceftriaxone in China's public medical institutions exceeded 3.
8 billion yuan in 2019.
At present, there are 5 over-rated companies for ceftriaxone sodium for injection, including Qilu Pharmaceutical, Kelun Pharmaceutical, Jincheng Jinsu Pharmaceutical, Runze Pharmaceutical and CSPC.
Up to now, CSPC has passed/deemed passed the consistency evaluation of 43 varieties (68 product specifications).
Data source: Mi Neiwang database, NMPA
Medical News, March 15th, March 11-12, NMPA official website shows that CSPC’s nintedanib ethanesulfonate soft capsules and entecavir tablets have been approved for production and deemed to have been reviewed.
Ceftriaxone sodium for injection passed Consistency evaluation.
Nintanib ethanesulfonate soft capsule is a targeted anti-fibrosis drug, and CSPC won the first domestic imitation.
At present, CSPC has already reviewed 43 products.
Ceftriaxone sodium for injection passed Consistency evaluation.
Nintanib ethanesulfonate soft capsule is a targeted anti-fibrosis drug, and CSPC won the first domestic imitation.
At present, CSPC has already reviewed 43 products.
Nintanib ethanesulfonate soft capsule is a multi-target tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim.
It is the world's first approved for the treatment of idiopathic pulmonary fibrosis (IPF) Of targeted drugs.
In 2019, Ofev's global sales were US$1.
670 billion.
It is the world's first approved for the treatment of idiopathic pulmonary fibrosis (IPF) Of targeted drugs.
In 2019, Ofev's global sales were US$1.
670 billion.
Nintedanib has been approved for multiple indications worldwide.
The approved indications in China include idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive Fibrotic interstitial lung disease (PF-ILD).
At present, only CSPC has submitted an imitation application for nintedanib ethanesulfonate soft capsules in the domestic market.
CSPC successfully won the first imitation, and the indication is IPF.
The product of Hausen Pharmaceuticals is undergoing BE trials and is expected to become the second domestic manufacturer.
The approved indications in China include idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive Fibrotic interstitial lung disease (PF-ILD).
At present, only CSPC has submitted an imitation application for nintedanib ethanesulfonate soft capsules in the domestic market.
CSPC successfully won the first imitation, and the indication is IPF.
The product of Hausen Pharmaceuticals is undergoing BE trials and is expected to become the second domestic manufacturer.
Entecavir is a guanine nucleoside analog, which has an inhibitory effect on hepatitis B virus reverse transcriptase, and has the advantages of good safety and tolerability.
It has been recommended as a first-line antiviral drug by many authoritative hepatitis B diagnosis and treatment guidelines around the world.
Entecavir has been included in the first batch of centralized procurement.
Affected by the sharp price cuts in centralized procurement, its market has shown a shrinking trend.
It has been recommended as a first-line antiviral drug by many authoritative hepatitis B diagnosis and treatment guidelines around the world.
Entecavir has been included in the first batch of centralized procurement.
Affected by the sharp price cuts in centralized procurement, its market has shown a shrinking trend.
Sales of terminal entecavir in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, the sales of terminal entecavir in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 7.
6 billion yuan, and its sales in 2020H1 exceeded 1.
4 billion yuan, year-on-year A decline of 62.
70%.
Currently, there are 11 companies that have reviewed Entecavir tablets .
com, in 2019, the sales of terminal entecavir in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 7.
6 billion yuan, and its sales in 2020H1 exceeded 1.
4 billion yuan, year-on-year A decline of 62.
70%.
Currently, there are 11 companies that have reviewed Entecavir tablets .
Ceftriaxone sodium is a long-acting, broad-spectrum third-generation semi-synthetic cephalosporin antibiotic.
It produces antibacterial effects by inhibiting the synthesis of cell walls, and has high antibacterial activity against most gram-negative and positive bacteria.
It produces antibacterial effects by inhibiting the synthesis of cell walls, and has high antibacterial activity against most gram-negative and positive bacteria.
According to data from Mi Nei.
com, the sales of terminal ceftriaxone in China's public medical institutions exceeded 3.
8 billion yuan in 2019.
At present, there are 5 over-rated companies for ceftriaxone sodium for injection, including Qilu Pharmaceutical, Kelun Pharmaceutical, Jincheng Jinsu Pharmaceutical, Runze Pharmaceutical and CSPC.
com, the sales of terminal ceftriaxone in China's public medical institutions exceeded 3.
8 billion yuan in 2019.
At present, there are 5 over-rated companies for ceftriaxone sodium for injection, including Qilu Pharmaceutical, Kelun Pharmaceutical, Jincheng Jinsu Pharmaceutical, Runze Pharmaceutical and CSPC.
Up to now, CSPC has passed/deemed passed the consistency evaluation of 43 varieties (68 product specifications).
Data source: Mi Neiwang database, NMPA
Medical News, March 15th, March 11-12, NMPA official website shows that CSPC’s nintedanib ethanesulfonate soft capsules and entecavir tablets have been approved for production and deemed to have been reviewed.
Ceftriaxone sodium for injection passed Consistency evaluation.
Nintanib ethanesulfonate soft capsule is a targeted anti-fibrosis drug, and CSPC won the first domestic imitation.
At present, CSPC has already reviewed 43 products.
Ceftriaxone sodium for injection passed Consistency evaluation.
Nintanib ethanesulfonate soft capsule is a targeted anti-fibrosis drug, and CSPC won the first domestic imitation.
At present, CSPC has already reviewed 43 products.
Nintanib ethanesulfonate soft capsule is a multi-target tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim.
It is the world's first approved for the treatment of idiopathic pulmonary fibrosis (IPF) Of targeted drugs.
In 2019, Ofev's global sales were US$1.
670 billion.
It is the world's first approved for the treatment of idiopathic pulmonary fibrosis (IPF) Of targeted drugs.
In 2019, Ofev's global sales were US$1.
670 billion.
Nintedanib has been approved for multiple indications worldwide.
The approved indications in China include idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive Fibrotic interstitial lung disease (PF-ILD).
At present, only CSPC has submitted an imitation application for nintedanib ethanesulfonate soft capsules in the domestic market.
CSPC successfully won the first imitation, and the indication is IPF.
The product of Hausen Pharmaceuticals is undergoing BE trials and is expected to become the second domestic manufacturer.
Disease disease diseaseThe approved indications in China include idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive Fibrotic interstitial lung disease (PF-ILD).
At present, only CSPC has submitted an imitation application for nintedanib ethanesulfonate soft capsules in the domestic market.
CSPC successfully won the first imitation, and the indication is IPF.
The product of Hausen Pharmaceuticals is undergoing BE trials and is expected to become the second domestic manufacturer.
Entecavir is a guanine nucleoside analog, which has an inhibitory effect on hepatitis B virus reverse transcriptase, and has the advantages of good safety and tolerability.
It has been recommended as a first-line antiviral drug by many authoritative hepatitis B diagnosis and treatment guidelines around the world.
Entecavir has been included in the first batch of centralized procurement.
Affected by the sharp price cuts in centralized procurement, its market has shown a shrinking trend.
It has been recommended as a first-line antiviral drug by many authoritative hepatitis B diagnosis and treatment guidelines around the world.
Entecavir has been included in the first batch of centralized procurement.
Affected by the sharp price cuts in centralized procurement, its market has shown a shrinking trend.
Sales of terminal entecavir in public medical institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, the sales of terminal entecavir in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 7.
6 billion yuan, and its sales in 2020H1 exceeded 1.
4 billion yuan, year-on-year A decline of 62.
70%.
Currently, there are 11 companies that have reviewed Entecavir tablets .
Hospital Hospital Hospital Enterprise Enterprise Enterprisecom, in 2019, the sales of terminal entecavir in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 7.
6 billion yuan, and its sales in 2020H1 exceeded 1.
4 billion yuan, year-on-year A decline of 62.
70%.
Currently, there are 11 companies that have reviewed Entecavir tablets .
Ceftriaxone sodium is a long-acting, broad-spectrum third-generation semi-synthetic cephalosporin antibiotic.
It produces antibacterial effects by inhibiting the synthesis of cell walls, and has high antibacterial activity against most gram-negative and positive bacteria.
It produces antibacterial effects by inhibiting the synthesis of cell walls, and has high antibacterial activity against most gram-negative and positive bacteria.
According to data from Mi Nei.
com, the sales of terminal ceftriaxone in China's public medical institutions exceeded 3.
8 billion yuan in 2019.
At present, there are 5 over-rated companies for ceftriaxone sodium for injection, including Qilu Pharmaceutical, Kelun Pharmaceutical, Jincheng Jinsu Pharmaceutical, Runze Pharmaceutical and CSPC.
com, the sales of terminal ceftriaxone in China's public medical institutions exceeded 3.
8 billion yuan in 2019.
At present, there are 5 over-rated companies for ceftriaxone sodium for injection, including Qilu Pharmaceutical, Kelun Pharmaceutical, Jincheng Jinsu Pharmaceutical, Runze Pharmaceutical and CSPC.
Up to now, CSPC has passed/deemed passed the consistency evaluation of 43 varieties (68 product specifications).
Data source: Mi Neiwang database, NMPA
